

# Stephen B Edge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3968818/publications.pdf>

Version: 2024-02-01

77  
papers

14,555  
citations

126907

33  
h-index

76900

74  
g-index

78  
all docs

78  
docs citations

78  
times ranked

19319  
citing authors

#	ARTICLE	IF	CITATIONS
1	Low RUFY3 expression level is associated with lymph node metastasis in older women with invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 19-32.	2.5	4
2	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. <i>Lancet Oncology</i> , The, 2022, 23, 149-160.	10.7	148
3	Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2~ Breast Cancer at a Single Cancer Center. <i>Oncologist</i> , 2022, 27, 646-654.	3.7	7
4	A Presurgical~Window Intervention Trial of Isothiocyanate~Rich Broccoli Sprout Extract in Patients with Breast Cancer. <i>Molecular Nutrition and Food Research</i> , 2022, , 2101094.	3.3	5
5	Behind the clock: elucidating factors contributing to longer clinic appointment duration and patient wait time. <i>BMC Health Services Research</i> , 2021, 21, 87.	2.2	1
6	Options to Determine Pathological Response of Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Advanced Breast Cancer. <i>Cancers</i> , 2021, 13, 4167.	3.7	6
7	Association between the 21-gene recurrence score and isolated locoregional recurrence in stage II, hormone receptor-positive breast cancer. <i>Radiation Oncology</i> , 2020, 15, 198.	2.7	4
8	Cancer Registration in Resource-limited Environments~Experience in Lagos, Nigeria. <i>Journal of Surgical Research</i> , 2019, 235, 167-170.	1.6	15
9	New and important changes in breast cancer TNM: incorporation of biologic factors into staging. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 309-318.	2.4	8
10	Oncologist uptake of comprehensive genomic profile guided targeted therapy. <i>Oncotarget</i> , 2019, 10, 4616-4629.	1.8	13
11	Efficacy of Palbociclib Combinations in Hormone Receptor~Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment. <i>Clinical Breast Cancer</i> , 2018, 18, e1401-e1405.	2.4	24
12	Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 751-759.	2.5	14
13	Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. <i>Journal of Oncology Practice</i> , 2018, 14, e194-e200.	2.5	29
14	New and Important Changes in the TNM Staging System for Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 457-467.	3.8	83
15	Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 4037-4046.	1.5	34
16	A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). <i>Annals of Surgical Oncology</i> , 2018, 25, 2587-2595.	1.5	8
17	American Society of Clinical Oncology Criteria for High-Quality Clinical Pathways in Oncology. <i>Journal of Oncology Practice</i> , 2017, 13, 207-210.	2.5	32
18	Establishing a Core Set of Performance Measures to Improve Value in Cancer Care: ASCO Consensus Conference Recommendation Report. <i>Journal of Oncology Practice</i> , 2017, 13, 135-140.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2017, , .		98
20	Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. <i>Cancer</i> , 2016, 122, 2091-100.	4.1	57
21	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 1258-1261.	2.5	6
22	Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 622-630.	0.8	77
23	Decision Making After BRCA Genetic Testing. <i>Clinical Journal of Oncology Nursing</i> , 2014, 18, E58-E63.	0.6	13
24	Quality measurement in breast cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 509-517.	1.7	9
25	Impact of Guideline Changes on Use or Omission of Radiation in the Elderly with Early Breast Cancer: Practice Patterns at National Comprehensive Cancer Network Institutions. <i>Journal of the American College of Surgeons</i> , 2014, 219, 796-802.	0.5	53
26	Case-only analyses of the associations between polymorphisms in the metastasis-modifying genes BRMS1 and SIPA1 and breast tumor characteristics, lymph node metastasis, and survival. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 873-885.	2.5	9
27	Completeness of American Cancer Registry Treatment Data: Implications for Quality of Care Research. <i>Journal of the American College of Surgeons</i> , 2013, 216, 428-437.	0.5	67
28	Using the American College of Surgeons Cancer Registry to Drive Quality. <i>Journal of Oncology Practice</i> , 2013, 9, 149-151.	2.5	7
29	Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions. <i>Journal of the National Cancer Institute</i> , 2013, 105, 104-112.	6.3	100
30	Advances in Breast Surgery, 2002-2012. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 53-59.	4.9	4
31	Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2218-2226.	1.6	114
32	Breast Education in General Surgery Residency. <i>American Surgeon</i> , 2012, 78, 42-45.	0.8	6
33	Reply to Letter of Shukla and Milsom. <i>Annals of Surgical Oncology</i> , 2011, 18, 300-300.	1.5	2
34	Surgery of the primary tumor does not improve survival in stage IV breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 459-465.	2.5	101
35	Race and Ethnicity are Associated with Delays in Breast Cancer Treatment (2003-2006). <i>Journal of Health Care for the Poor and Underserved</i> , 2011, 22, 128-141.	0.8	76
36	The Anticipated and Unintended Consequences of the Patient Protection and Affordable Care Act on Cancer Research. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 606-613.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Breast Cancer: Noninvasive and Special Situations. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1182-1207.	4.9	8
38	The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology, 2010, 17, 1471-1474.	1.5	7,085
39	Claims data linked to hospital registry data enhance evaluation of the quality of care of breast cancer. Journal of Surgical Oncology, 2010, 101, 593-599.	1.7	18
40	Factors Associated With Guideline-Concordant Use of Radiotherapy After Mastectomy in the National Comprehensive Cancer Network. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1434-1440.	0.8	39
41	American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. Journal of Clinical Oncology, 2008, 26, 3631-3637.	1.6	205
42	Early Adoption and Disturbing Disparities in Sentinel Node Biopsy in Breast Cancer. Journal of the National Cancer Institute, 2008, 100, 449-450.	6.3	2
43	Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5553-5560.	1.6	32
44	Evidence and Controversies in the Use of Post-Mastectomy Radiation. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 331-338.	4.9	12
45	Linked claims and medical records for cancer case management. Cancer, 2007, 110, 518-524.	4.1	4
46	Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. Journal of Surgical Oncology, 2006, 93, 129-132.	1.7	50
47	BI-RADS Classification for Management of Abnormal Mammograms. Journal of the American Board of Family Medicine, 2006, 19, 161-164.	1.5	117
48	American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2005, 23, 7703-7720.	1.6	1,674
49	Lymphedema Secondary to Postmastectomy Radiation: Incidence and Risk Factors. Annals of Surgical Oncology, 2004, 11, 573-580.	1.5	135
50	The role of the surgeon in quality cancer care. Current Problems in Surgery, 2003, 40, 511-590.	1.1	7
51	Effect of stereotactic core needle biopsy on pathologic measurement of tumor size of T1 invasive breast carcinomas presenting as mammographic masses. Cancer, 2003, 97, 2137-2141.	4.1	12
52	Emergence of Sentinel Node Biopsy in Breast Cancer as Standard-of-Care in Academic Comprehensive Cancer Centers. Journal of the National Cancer Institute, 2003, 95, 1514-1521.	6.3	94
53	Mammographic Predictors of the Presence and Size of Invasive Carcinomas Associated With Malignant Microcalcification Lesions Without a Mass. American Journal of Roentgenology, 2003, 181, 1679-1684.	2.2	76
54	Counterpoint: Sentinel Lymph Node Biopsy Is Not Indicated for Ductal Carcinoma In Situ. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 207-212.	4.9	9

#	ARTICLE	IF	CITATIONS
55	Update: breast cancer guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1 Suppl 3, S-3-8.	4.9	0
56	Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3628-3636.	1.6	1,035
57	Patient and provider characteristics that affect the use of axillary dissection in older women with Stage I-II breast carcinoma. Cancer, 2002, 94, 2534-2541.	4.1	41
58	Provider case volume and outcome in the evaluation and treatment of patients with mammogram-detected breast carcinoma. Cancer, 2002, 95, 704-712.	4.1	35
59	Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. Cancer, 2002, 95, 2445-2454.	4.1	42
60	Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*. Journal of Clinical Oncology, 2001, 19, 1539-1569.	1.6	742
61	Measuring and Predicting Surgeons??? Practice Styles for Breast Cancer Treatment in Older Women. Medical Care, 2001, 39, 228-242.	2.4	72
62	Intraoperative Pathologic Evaluation of a Breast Cancer Sentinel Lymph Node Biopsy as a Determinant for Synchronous Axillary Lymph Node Dissection. Annals of Surgical Oncology, 2001, 8, 361-367.	1.5	74
63	Defining Core Information for the Training and Continuing Education of Surgical Oncologists. Annals of Surgical Oncology, 2001, 8, 562-563.	1.5	2
64	Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma. Journal of Surgical Oncology, 2001, 77, 243-246.	1.7	32
65	Simple technique of early identification of the thoracodorsal nerve during axillary dissection. Journal of Surgical Oncology, 2001, 76, 141-142.	1.7	4
66	Downregulation of Gelsolin Correlates with the Progression to Breast Carcinoma. Breast Cancer Research and Treatment, 2001, 65, 11-21.	2.5	78
67	Patterns of breast carcinoma treatment in older women. Cancer, 2000, 89, 561-573.	4.1	264
68	Postexcision Mammography Is Indicated After Resection of Ductal Carcinoma-In-Situ of the Breast. Annals of Surgical Oncology, 2000, 7, 665-668.	1.5	31
69	Patterns of breast carcinoma treatment in older women. Cancer, 2000, 89, 561-573.	4.1	9
70	Prognostic Factors in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2000, 124, 966-978.	2.5	916
71	Downregulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. Breast Cancer Research and Treatment, 1999, 55, 177-186.	2.5	43
72	Laparoscopic cholecystectomy and unsuspected gallbladder carcinoma. , 1999, 16, 327-331.		35

#	ARTICLE	IF	CITATIONS
73	Sentinel node biopsy in breast cancer. <i>Annals of Surgical Oncology</i> , 1998, 5, 126-130.	1.5	209
74	Cellular proliferative activity of mammographic normal dense and fatty tissue determined by DNA S phase percentage. <i>Breast Cancer Research and Treatment</i> , 1996, 37, 229-236.	2.5	11
75	Endometrial carcinoma associated with breast carcinoma: Low incidence with tamoxifen use. <i>Cancer</i> , 1996, 77, 2058-2063.	4.1	37
76	Endometrial carcinoma associated with breast carcinoma: Low incidence with tamoxifen use. <i>Cancer</i> , 1996, 77, 2058-2063.	4.1	5
77	In situ breast carcinoma after treatment during adolescence for thyroid cancer with radioiodine. <i>Medical and Pediatric Oncology</i> , 1995, 24, 82-86.	1.0	11